New review explores the role of antibodies and T-cells towards an effective COVID vaccine

New review explores the role of antibodies and T-cells towards an effective COVID vaccine

New review explores the role of antibodies and T-cells towards an effective COVID vaccine

More than 100 companies have rushed into vaccine development against COVID-19 as the U.S. government pushes for a vaccine rollout at "warp speed" -- possibly by the end of the year -- but the bar set for an effective, long-lasting vaccine is far too low and may prove dangerous, according to Marc Hellerstein of the University of California, Berkeley.